Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.

Drugs
Gillian M Keating

Abstract

Peginterferon-alpha-2a (40 kD) [Pegasys] comprises an inert, branched, 40 kD polyethylene glycol (PEG) moiety attached to interferon-alpha-2a. Subcutaneous peginterferon-alpha-2a (40 kD) is indicated for the treatment of adults with hepatitis B e antigen (HBeAg)-positive or -negative chronic hepatitis B who have compensated liver disease with evidence of viral replication and hepatic inflammation. Subcutaneous peginterferon-alpha-2a (40 kD) has antiviral and immunomodulatory properties and a convenient once-weekly administration schedule. Forty-eight weeks of therapy with peginterferon-alpha-2a (40 kD) with or without lamivudine was more effective than lamivudine alone in achieving a sustained response in patients with HBeAg-positive or -negative chronic hepatitis B. A long-term follow-up study in patients with HBeAg-positive disease who received peginterferon-alpha-2a (40 kD) monotherapy revealed an HBeAg seroconversion rate of 42%, 1 year after the end of treatment. A long-term follow-up study in patients with HBeAg-negative disease who received peginterferon-alpha-2a (40 kD) with or without lamivudine revealed hepatitis B surface antigen (HBsAg) clearance in 12% of patients and inactive chronic hepatitis B in 17% of patients...Continue Reading

References

Dec 7, 2000·The New England Journal of Medicine·S ZeuzemM J Brunda
Dec 7, 2000·The New England Journal of Medicine·E J HeathcoteJ De Pamphilis
Feb 15, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K R ReddyJ DePamphilis
Aug 21, 2001·Clinical Pharmacokinetics·J M HarrisM Modi
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Sep 17, 2004·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
Jan 11, 2005·Lancet·Harry L A JanssenUNKNOWN Rotterdam Foundation for Liver Research
Jul 1, 2005·The New England Journal of Medicine·George K K LauUNKNOWN Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
Jul 15, 2005·Expert Opinion on Pharmacotherapy·W Graham E Cooksley
Jul 14, 2006·Antiviral Research·Bart L Haagmans, Albert D M E Osterhaus
Nov 28, 2006·Gut·F BoninoUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
Jul 31, 2007·The American Journal of Gastroenterology·Robert G GishRobert Perrillo
Jan 29, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michael W FriedMatei Popescu
Mar 15, 2008·Liver International : Official Journal of the International Association for the Study of the Liver·Patrick MarcellinNigel Pluck
Apr 3, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David L VeenstraKavita K Patel
Apr 10, 2008·Journal of Gastroenterology and Hepatology·Laurence LaceyRaoh-Fang Pwu
Dec 5, 2008·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver
Dec 31, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Rami MoucariPatrick Marcellin
Mar 24, 2009·Gastroenterology·Patrick MarcellinUNKNOWN Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group
Mar 31, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert P Perrillo
Apr 2, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maurizia Rossana BrunettoPatrick Marcellin
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brian J McMahon
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Karin L Andersson, Raymond T Chung
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G Ghany, Edward C Doo
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jules L Dienstag
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norah A Terrault
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Bulent Degertekin, Anna S F Lok
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordan J FeldE Jenny Heathcote
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert J Fontana
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michael F SorrellHartwell T Trotter
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert Perrillo
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T Jake Liang
Aug 12, 2009·Hepatology International·Yun-Fan LiawUNKNOWN Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver
Aug 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F Lok, Brian J McMahon
Oct 27, 2009·Drugs·Grace L-H Wong, Henry L-Y Chan

❮ Previous
Next ❯

Citations

Mar 21, 2013·Journal of Clinical Immunology·H I BaxE P Sampaio
Aug 6, 2015·Protein Engineering, Design & Selection : PEDS·Gurdip K DaffuJoanne Macdonald
Mar 31, 2015·Indian Journal of Pharmacology·Hasan Tahsin Gozdas, Oguz Karabay
Nov 28, 2019·Seminars in Immunology·Ben X Wang, Eleanor N Fish

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.